Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piperacillin-Tazobactam Labatec
- Development stage
- Unknown
- Lead developer
- Labatec Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Piperacillin-Tazobactam Labatec is an approved combination antibiotic product developed and marketed by Labatec Pharma. It contains piperacillin, a broad-spectrum ureidopenicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Piperacillin exerts its bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), which prevents the final stage of peptidoglycan cross-linking. Tazobactam protects piperacillin from degradation by irreversibly inhibiting many beta-lactamase enzymes that are commonly responsible for resistance to penicillins and cephalosporins. This combination is indicated for the treatment of various serious mixed bacterial infections, including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, bacterial sepsis, and infections in neutropenic patients. It is formulated as a powder for intravenous infusion.
- Brand names
- Piperacillin-Tazobactam Labatec
- Other names
- Piperacillin-Tazobactam
02
Targets
β-lactamasePBP3 (Peptidoglycan D,D-transpeptidase FtsI)
Beyond the preview
Go deeper on Piperacillin-Tazobactam Labatec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Piperacillin-Tazobactam Labatec.